E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
non-functioning pituitary adenomas |
|
E.1.1.1 | Medical condition in easily understood language |
pituitary tumours with no hormone production |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Hormonal diseases [C19] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10035079 |
E.1.2 | Term | Pituitary adenoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To study the effect of medical treatment with cabergoline on tumour volume in non-functioning pituitary adenomas. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the effect of medical treatment with cabergoline in non-functioning pituitary adenomas on pituitary function, and on the need for non-medical treatment. To evaluate possible complications to dopamine agonist treatment in non-functioning pituitary adenomas. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. A previously untreated non-functioning pituitary macroadenoma (largest diameter ≥ 10 mm) OR a residual tumour after surgical treatment of a non-functioning pituitary macroadenoma
2. Age 18-75 years
|
|
E.4 | Principal exclusion criteria |
1. Clear indication for surgery at the time of inclusion
2. Radiation therapy the last 2 years prior to inclusion, or radiation therapy >2 years earlier if significant tumour shrinkage after treatment
3. Pituitary surgery the last 6 months
4. Apoplexy/bleeding in the adenoma
5. Pregnancy or lactation
6. Contraindications for cabergoline treatment:
Known cardiac valvular disease
Known pulmonal, pericardial or retroperitoneal fibrosis
Clinical significant liver insufficiency
Use of medications that interact with cabergoline
7. Unfit to participate due to any other reason
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The change in tumour volume during the study. This includes the percentage and absolute change in tumour volume, but also the number of patients with significant tumour shrinkage or tumour growth. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At 2 years (at cross-over) and 4 years (end of study).
Interim analyses will be performed after one year to ensure and document safety. |
|
E.5.2 | Secondary end point(s) |
• The need for surgical and/or radiation treatment during the study period.
• The development of new or changed pituitary failure during the study, or new or changed visual field defects or other cranial nerve affections.
• The change in tumour’s distance to chiasma opticum (mm).
• The response on gonadotropins (FSH, LH) and/or their subunits, particularly the α-subunit. We will also examine a possible correlation between the tumour size response and the hormone levels and hormone response during treatment.
• The development of cardiac valvulopathy
• The development of impulse control disorder.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At 2 years (at cross-over) and 4 years (end of study).
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of clinical phase of trial: the last visit of the last subject. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |